ADVERTISEMENT
Pharma Q3 Preview — Nirmal Bang Projects U.S. Pricing Pressure To Ease; Lists Stocks To Buy, Sell, Hold
The U.S. business is expected to grow by ~8% YoY in CC terms mainly on the back of gRevlimid and gSpiriva and new launches, but it is expected to remain almost flat QoQ, adds the brokerage.
15 Jan 2025, 05:59 PM IST 
Domestic market’s weak volume growth was partially covered by price hikes in Chronic therapies.
(Photo Source: Freepik)
Among the Large Caps, all coverage companies are expected to report decent numbers. In terms of revenue, Zydus, Dr. Reddy's, Mankind (due to acquisition) and Torrent Pharma are expected to report >10% YoY growth among the large caps while Eris Lifesciences /JB Chememicals (due to acquisitions) are expected to report strong double-digit YoY revenue growth in the mid cap/small cap space.
